USPTO Examiner WILSON JERICA KATLYNN - Art Unit 1621

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18968101SUBSTITUTED PHENYL OXAZOLONE COMPOUNDSDecember 2024April 2025Allow510NoNo
18914691ARYL-1,2,3-TRIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITION THEREOF AND METHOD FOR TREATMENT OF BREAST CANCEROctober 2024January 2025Allow310NoNo
18676679POLYMORPHS OF PHENYL PYRROLE AMINOGUANDIUM SALTSMay 2024January 2025Allow821YesNo
18663952PRMT5 INHIBITORS AND USES THEREOFMay 2024February 2025Allow911NoNo
18646687THIOAMIDE DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOFApril 2024October 2024Allow610NoNo
18634599IMIDAZOTRIAZINE THIOBENZAMIDE DERIVATIVE, AND PREPARATION METHOD AND APPLICATION THEREOFApril 2024November 2024Allow710NoNo
18131183LYSYL OXIDASE INHIBITORS FOR TREATING MYELOID MALIGNANCIESApril 2023October 2024Allow1820NoNo
18187789PYRIMID-2-YL-PYRAZOLE COMPOUNDS AS IRAK INHIBITORSMarch 2023April 2025Allow2421YesNo
18182234INHIBITORS OF NITRIC OXIDE SYNTHASES (NOS), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOFMarch 2023January 2025Allow2321YesNo
18161609PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOFJanuary 2023May 2024Abandon1510NoNo
18145618DEUBIQUITINASE INHIBITORS AND METHODS OF USE THEREOFDecember 2022February 2025Allow2621NoNo
17897388CO-CRYSTALSAugust 2022October 2024Allow2520YesNo
17816950PENTADECANOYLCARNITINE FOR TREATMENT OF CONDITIONS RELATED TO THE QUALITY OF AGING AND LONGEVITYAugust 2022December 2024Allow2921NoNo
17857706COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOFJuly 2022August 2024Allow2511YesNo
17846693CANNABIDIOL-BASED TOPICAL REMEDYJune 2022January 2025Abandon3120NoNo
17776040ANTIMALARIAL AGENTSMay 2022March 2025Allow3400YesNo
17740275METHOD FOR CONTINUOUSLY PREPARING N,N-BIS(2,2,6,6-TETRAMETHYL-4-PIPERIDYL)-1,6-HEXAMETHYLENEDIAMINEMay 2022May 2024Allow2410NoNo
17774662Application of Boron Dipyrromethene Derivatives in Anti-Tumor and Anti-Bacterial TherapyMay 2022March 2025Allow3520YesNo
176153631,3,4-OXADIAZOLE HOMOPHTHALIMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAMENovember 2021June 2025Allow4210YesNo
17610867SUSTAINED-RELEASE MICROGEL OINTMENTS WITH HIGH DRUG LOADING AND PREPARATION METHODS AND USES THEREOFNovember 2021February 2025Allow4010NoNo
17519922Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2November 2021April 2025Abandon4210NoNo
17606319CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASEOctober 2021April 2025Allow4110NoNo
17602057HEXAHYDRO-1H-PYRAZINO[1,2-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASEOctober 2021January 2025Allow4010NoNo
17435276METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORSAugust 2021March 2025Abandon4310NoNo
17461325FATTY ACID ANALOGS AND THEIR USE IN THE TREATMENT OF COGNITIVE IMPAIRMENT, BEHAVIORAL CONDITIONS, AND CHRONIC PAINAugust 2021May 2025Allow4420YesNo
17045409COMPOSITION FOR PREVENTING AND TREATMENT OF STROKEAugust 2021December 2024Abandon5010NoNo
17430060TRIAMTERENE OR NOLATREXED FOR USE IN THE TREATMENT OF PHENYLKETONURIAAugust 2021December 2024Allow4010NoNo
17429575PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ACIDOSISAugust 2021May 2025Abandon4510NoNo
17310181CANNABIDIOL AND/OR DERIVATIVES THEREOF FOR USE IN THE TREATMENT OF MITOCHONDRIAL DISEASESJuly 2021April 2025Allow4520NoNo
17421741DIHYDROOROTATE DEHYDROGENASE INHIBITORSJuly 2021April 2025Abandon4510NoNo
17415085AGENT FOR IMPROVING INFERTILITY, RECURRENT MISCARRIAGE, AND STATE OF PREGNANCYJune 2021June 2025Abandon4820NoNo
17414404ORAL THERAPY USING 6,8-BIS-BENZYLTHIO-OCTANOIC ACIDJune 2021June 2025Abandon4820NoNo
17413346METHOD FOR PRODUCING REFINED PRODUCT OF PEAR JUICEJune 2021February 2025Abandon4501NoNo
17344830KINASE INHIBITORS AND METHODS OF USE THEREOFJune 2021April 2025Allow4621YesNo
17312898STABLE FORMULATIONS OF ANESTHETICS AND ASSOCIATED DOSAGE FORMSJune 2021November 2024Abandon4110NoNo
17341817KINASE INHIBITORS AND METHODS FOR MAKING AND USINGJune 2021September 2024Abandon4001NoNo
17341158SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENTJune 2021October 2024Abandon4110NoNo
17340082BICYCLIC SULFONES AND SULFOXIDES AND METHODS OF USE THEREOFJune 2021February 2025Allow4411NoNo
17298198ELACESTRANT IN COMBINATION WITH ABEMACICLIB IN WOMEN WITH BREAST CANCERMay 2021June 2025Abandon4820NoNo
17294353INHIBITORS OF ARG1 AND/OR ARG2May 2021October 2024Allow4110NoNo
17292528HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSYMay 2021March 2025Allow4621NoNo
17292511SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USEMay 2021May 2025Allow4811YesNo
17292480COMBINATION OF A MCL-1 INHIBITOR AND MIDOSTAURIN, USES AND PHARMACEUTICAL COMPOSITIONS THEREOFMay 2021November 2024Abandon4311NoNo
17292677MICROMOLECULAR COMPOUND SPECIFICALLYDEGRADING TAU PROTEIN, AND APPLICATION THEREOFMay 2021October 2024Allow4110NoNo
17313885EPINEPHRINE SPRAY FORMULATIONSMay 2021January 2025Allow4410YesNo
17245240GASTRIC CANCER TREATMENTSApril 2021September 2024Abandon4111NoNo
17289406TRIFLUOROMETHYL-SUBSTITUTED SULFONAMIDE AS BCL-2-SELECTIVE INHIBITORApril 2021February 2025Allow4521NoNo
17288063UPADACITINIB CRYSTAL FORM AND PREPARATION METHOD THEREFOR AND USE THEREOFApril 2021August 2024Abandon4001NoNo
17286904PPAR delta ACTIVATORApril 2021December 2024Allow4420NoNo
17286932SYNTHESIS OUTSIDE HIGH AND LOW TEMPERATURE EQUILIBRIUM BY SPRAY FLASH SYNTHESISApril 2021November 2024Allow4310YesNo
17231168Novel Phenyl DerivativesApril 2021October 2024Abandon4201NoNo
17285780PROCESS FOR PRODUCING ETHYLENE OXIDE BY GAS-PHASE OXIDATION OF ETHYLENEApril 2021August 2024Allow4010NoNo
17285414COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING A GROWTH RELATED DISEASE AND/OR A CLINICAL CONDITION THEREOFApril 2021August 2024Abandon4010NoNo
17285180COMPOUND AS TGF-beta R1 INHIBITOR AND APPLICATION THEREOFApril 2021July 2024Abandon3901NoNo
17229036SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORSApril 2021September 2024Abandon4111NoNo
17224025SHP2 INHIBITOR COMPOSITIONS FOR USE IN TREATING CANCERApril 2021August 2024Abandon4001NoNo
172803533-AZABICYCLO[3,1,1]HEPTANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAMEMarch 2021July 2024Allow3910NoNo
17278017NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE SKELETON, HAVING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION INHIBITORY EFFECTMarch 2021January 2025Allow4621NoNo
17276459COMBINATION THERAPY FOR TREATING BLOOD CANCERMarch 2021May 2024Allow3810NoNo
17275450IMMUNOMODULATORS, COMPOSITIONS AND METHODS THERE OFMarch 2021June 2024Allow4011NoNo
17275604COMBINATION OF PARP INHIBITOR AND BRD4 INHIBITOR FOR THE TREATMENT OF CANCERMarch 2021June 2024Abandon3910NoNo
17274736NOVEL INHIBITORS OF GUANOSINE MONOPHOSPHATE SYNTHETASE AS THERAPEUTIC AGENTSMarch 2021October 2024Allow4411YesNo
17273646METHODS OF TREATING CYTOKINE RELEASE SYNDROMEMarch 2021June 2024Abandon3901NoNo
17268042BIOMARKERS FOR CANCER THERAPYFebruary 2021August 2024Allow4211YesNo
17261938DEUTERATED DERIVATIVES OF LANIFIBRANORJanuary 2021March 2025Allow4920YesNo
17259795COMPOUNDS FOR USE IN THE TREATMENT OF FASCIOLIASISJanuary 2021April 2024Allow3910YesNo
17047169COMPOSITIONS AND METHODS FOR TREATMENT OF DEMYELINATIONOctober 2020January 2025Abandon5201NoNo
16768031Sulfonamide Compounds and Use ThereofMay 2020December 2024Allow5511NoNo

Appeals Overview

No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.

Examiner WILSON, JERICA KATLYNN - Prosecution Strategy Guide

Executive Summary

Examiner WILSON, JERICA KATLYNN works in Art Unit 1621 and has examined 62 patent applications in our dataset. With an allowance rate of 59.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner WILSON, JERICA KATLYNN's allowance rate of 59.7% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WILSON, JERICA KATLYNN receive 1.16 office actions before reaching final disposition. This places the examiner in the 18% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WILSON, JERICA KATLYNN is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +54.3% benefit to allowance rate for applications examined by WILSON, JERICA KATLYNN. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 90.0% of cases where such amendments are filed. This entry rate is in the 98% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Petition Practice

When applicants file petitions regarding this examiner's actions, 60.0% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 21.6% of allowed cases (in the 93% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.